ERDITI initiative

ERDITI (The European Rare Disease Therapeutic Initiative) is an innovative partnership between European academic institutions and pharmaceutical companies, established to develop drugs for the treatment of rare diseases and to facilitate the evaluation of compounds that have been or are being developed by pharmaceutical companies. The 3 main goals of ERDITI are : a) to give academic teams an access to a large variety of compounds; b) to provide a collaboration streamlined facilitated process between academic teams and Pharma Partner to develop drugs for rare diseases; c) to guarantee the continuity all the way from research to development and commercialisation of the drug. There is an opened procedure for applying for compounds. It is intended for European academic scientists holding project on a rare disease, or a defined group of rare diseases, who would like access to compounds that have been or are being developed by pharmaceutical companies. A scientific advisory board will assess the suitability of the request. More information about how to apply for compounds can be found here. An interesting article, published recently in PLoS Medicine, about ERDITI can be downloaded here.